Home >> Research Area >>GPCR/G protein>>Vasopressin Receptor>> (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Selective vasopressin V1A antagonist CAS# 73168-24-8

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Catalog No. BCC6011----Order now to get a substantial discount!

Product Name & Size Price Stock
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 5mg $782 In Stock
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 10mg Please Inquire In Stock
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 20mg Please Inquire Please Inquire
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 50mg Please Inquire Please Inquire
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 100mg Please Inquire Please Inquire
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 200mg Please Inquire Please Inquire
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 500mg Please Inquire Please Inquire
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Number of papers citing our products

Chemical structure

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

3D structure

Chemical Properties of (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Cas No. 73168-24-8 SDF Download SDF
PubChem ID 9833460 Appearance Powder
Formula C52H74N14O12S2 M.Wt 1151.38
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 2 mg/ml in water
Sequence YFQNCPRG

(Modifications: Tyr-1 = Pmp-Tyr(Me), Gly-8 = C-terminal amide)

Chemical Name (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(10R,13S,16S,19S,22S)-13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-benzyl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
SMILES COC1=CC=C(C=C1)CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCCC4C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC5=CC=CC=C5
Standard InChIKey QVQOGNOOAMQKCE-ZTYVOHGWSA-N
Standard InChI InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

DescriptionSelective vasopressin V1A receptor antagonist. Inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and induces anxiolytic-like effects in the dorsal, but not ventral, hippocampus in vivo.

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.[Pubmed:18508119]

Neuropeptides. 2008 Aug;42(4):411-21.

Arginine-vasopressin (AVP) is synthesized and released centrally in several brain structures. AVP is thought to mediate anxiety-related behavior through two central receptor subtypes, Avpr1a and Avpr1b. Although these AVP receptor subtypes are expressed in several brain regions, including the hippocampus, little is known about their explicit role in unconditioned fear or anxiety. This experiment assessed the anxiety-related effects of a selective Avpr1a antagonist ([beta-Mercapto-beta,beta-cyclopentamethylenepropionyl1, O-me-Tyr2, Arg8]-AVP) and a selective Avpr1b antagonist ((2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo -2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide; SSR 149415) microinfused into either the dorsal or ventral sub-regions of the rat hippocampus. Avpr1a antagonism in the ventral, but not the dorsal hippocampus reduced rats' anxiety-like behavior in the elevated plus-maze test. Conversely, Avpr1b antagonism in the dorsal, but not the ventral, hippocampus reduced anxiety in the plus-maze test. Neither antagonist reduced anxiety-like behavior in the shock-probe burying test. Overall, the results show that both receptor subtypes of AVP are involved in anxiety-related responses, but their specific contributions depend on three variables: (1) the anxiety-related response (shock-probe avoidance versus open-arm avoidance), (2) the receptor subtype antagonized (Avpr1a versus Avpr1b), and (3) the area of hippocampus (dorsal versus ventral) into which these antagonists are infused. These dissociations suggest that different fear responses are under the control of specific AVP receptor systems within discrete parts of the hippocampus.

Vasopressin inhibits sarcolemmal ATP-sensitive K+ channels via V1 receptors activation in the guinea pig heart.[Pubmed:11922278]

Circ J. 2002 Mar;66(3):277-82.

To examine the effect of vasopressin on the sarcolemmal ATP-sensitive K (K(ATP)) channel, cell-attached, insideout and open-cell-attached methods of patch clamp techniques were used in isolated guinea pig ventricular myocytes. Suppressing both glycolytic and oxidative ATP production attained K(ATP) channel activation. In the cell-attached mode, vasopressin inhibited KATP channels in a concentration-dependent manner with an IC50 of 15.1+/-1.8 nmol/L. In the inside-out configuration, vasopressin failed to block K(ATP) channels. In the cell-attached mode, manning compound (1 micromol/L), a V1 receptor-selective antagonist, blocked the inhibitory action of vasopressin, although OPC-31260 (1 micromol/L), a V2 receptor-selective antagonist could not affect the action of vasopressin. In addition, vasopressin lost its inhibitory action on K(ATP) channels when the channel was activated by pinacidil, a K channel opener and in the open-cell-attached mode effected by streptolysin-O. Thus, the inhibitory action of vasopressin K(ATP) channels may occur via V1 receptor related mechanism.

Arginine vasopressin and oxytocin increase intracellular calcium and cAMP in human glomerular epithelial cells in culture.[Pubmed:8871886]

Kidney Blood Press Res. 1996;19(2):81-6.

The signal transduction linkages of arginine vasopressin (AVP) and oxytocin receptors were investigated in human glomerular epithelial cells (GEC) in culture. AVP (ED50, 10(-7) mol/l) and oxytocin (ED50, 3 x 10(-8) mol/l) induced a rapid, transient and dose-dependent increase in [Ca2+]i as detected by fura-2 microfluorimetry. The baseline of [Ca2+]i in human GEC was 109 +/- 2.8 nmol/l (n = 60). The V1a receptor antagonist [d(CH2)5(1), Tyr(Me)2, Arg8]-vasopressin inhibited the AVP-(IC50, 5 x 10(-9) mol/l) and oxytocin-induced (IC50, 3 x 10(-8) mol/l) increase in [Ca2+]i in a dose-dependent manner. Both, AVP and oxytocin caused accumulation of cAMP. The AVP-stimulated cAMP increase was blocked by pretreatment of human GEC with the V1a receptor antagonist (10(-7) mol/l), whereas the oxytocin-induced cAMP accumulation remained uninfluenced. In conclusion the present results indicate that: (1) V1a receptor activation, AVP and oxytocin induce a transient elevation in [Ca2+]i in human GEC; (2) AVP and oxytocin cause cAMP accumulation; (3) the AVP-induced cAMP accumulation is inhibited by a V1a receptor antagonist, whereas (4) the oxytocin response showed no effect. In addition, a different receptor might be possible, at least in oxytocin-induced-cAMP accumulation.

Keywords:

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin,73168-24-8,Natural Products,Vasopressin Receptor, buy (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin , (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin supplier , purchase (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin , (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin cost , (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin manufacturer , order (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin , high purity (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: